5. Progressive supranuclear palsy
[
55 clinical trials,
78 drugs（DrugBank:
31 drugs),
59 target genes / 86 target pathways ]
Searched query = "Progressive supranuclear palsy"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04008355 | October 11, 2019 | 2 September 2019 | A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: AZP2006 oral solution;Drug: Placebo oral solution | AlzProtect SAS | Not recruiting | 40 Years | 80 Years | All | 36 | Phase 2 | France | |
| 2 | NCT03926702 | June 18, 2019 | 22 July 2019 | Tau Imaging With JNJ067 | Tau Imaging With JNJ067 | Alzheimer Disease;Mild Cognitive Impairment;Progressive Supranuclear Palsy | Drug: Radiopharmaceuticals | University of California, Berkeley | University of California, San Francisco | Recruiting | 50 Years | N/A | All | 18 | Early Phase 1 | United States |
| 3 | JPRN-UMIN000036952 | 2019/06/04 | 16 July 2019 | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others. | 18F-FDOPA, 11C-Raclopride PET | Nagoya City Rehabilitation Agency | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan | |
| 4 | NCT04014387 | June 2, 2019 | 29 July 2019 | Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) | Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) | Treatment | Drug: Suvorexant;Drug: Zolpidem;Drug: Placebo oral capsule | University of California, San Francisco | US Department of Veterans Affairs | Recruiting | 18 Years | N/A | All | 60 | Phase 4 | United States |
| 5 | JPRN-UMIN000036522 | 2019/04/15 | 23 April 2019 | Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug | Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug - Clinical trial for PSP using anticholinergic drug | Progressive supranuclear palsy | Trihexyphenidyl hydrochloride max.3mg for 3 months Placebo max. 3mg for 3 months | 1) Department of Neurology, Gifu University Graduate School of Medicine, 2) National Hospital Organization, Higashi Nagoya Hospital | Recruiting | 40years-old | Not applicable | Male and Female | 32 | Not selected | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | JPRN-jRCTs051180214 | 29/03/2019 | 10 September 2019 | The usefulness of flutemetamol for diagnostic imaging of neurogenerative disease | The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease | Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy | Amyloid PET: Given the flutemetamol (3mL) intravenously FDG-PET:Given the FDG scanR (3mL) intravenously | Yoshiaki Itoh | Recruiting | Ages 20 and over | N/A | Both | 100 | N/A | none | |
| 7 | JPRN-UMIN000034834 | 2019/01/01 | 2 April 2019 | Detection of falling risk of progressive supranuclear palsy with inertial sensor | progressive supranuclear palsy | Measurement of muscle strength, balance test, gait analysis | Kawasaki University of Medical Welfare | Not Recruiting | Not applicable | Not applicable | Male and Female | 20 | Not selected | Japan,Europe | ||
| 8 | NCT03413319 | April 17, 2018 | 18 December 2018 | Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 | Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 | Progressive Supranuclear Palsy (PSP) | Drug: ABBV-8E12 | AbbVie | Not recruiting | 18 Years | N/A | All | 3 | Phase 1 | United States | |
| 9 | NCT03446807 | April 2018 | 11 June 2018 | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Droxidopa;Drug: Placebo Oral Tablet | Loma Linda University | H. Lundbeck A/S | Not recruiting | 50 Years | N/A | All | 32 | Phase 2 | United States |
| 10 | NCT03545789 | March 12, 2018 | 1 April 2019 | Phase 1 Test-retest Evaluation of [18F]MNI-958 PET | Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers | Healthy Volunteers;Alzheimer Disease;Progressive Supranuclear Palsy | Drug: [18F]MNI-958 | Invicro | Recruiting | 18 Years | 55 Years | All | 14 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT03391765 | January 24, 2018 | 26 August 2019 | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy (PSP) | Drug: ABBV-8E12 | AbbVie | Not recruiting | 40 Years | N/A | All | 142 | Phase 2 | United States;Australia;Canada;France;Italy;Japan | |
| 12 | NCT03625128 | January 2, 2018 | 28 October 2019 | 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls | Phase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls | Alzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive Impairment | Drug: F-18 | Chang Gung Memorial Hospital | Not recruiting | 20 Years | 90 Years | All | 36 | Early Phase 1 | Taiwan | |
| 13 | NCT03545126 | August 21, 2017 | 7 October 2019 | Human CNS Tau Kinetics in Tauopathies | Human CNS Tau Kinetics in Tauopathies | Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD);Frontotemporal Dementia (FTD MAPT Mutation) | Other: 13C6 Leucine | Washington University School of Medicine | Association of Frontotemporal Degeneration;Tau Consortium | Recruiting | 18 Years | N/A | All | 32 | N/A | United States |
| 14 | NCT03174938 | May 15, 2017 | 11 June 2018 | The Swedish BioFINDER 2 Study | The Swedish BioFINDER 2 Study | Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment | Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau | Skane University Hospital | Lund University | Recruiting | 20 Years | 100 Years | All | 1505 | N/A | Sweden |
| 15 | NCT03068468 | April 24, 2017 | 30 September 2019 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy | Supranuclear Palsy, Progressive | Drug: BIIB092;Drug: Placebo | Biogen | Not recruiting | 41 Years | 86 Years | All | 490 | Phase 2 | United States;Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2017-000094-36-SE | 31/03/2017 | 22 May 2017 | The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disorders | The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders | Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and mild cognitive impairment. MedDRA version: 19.1 Level: PT Classification code 10053643 Term: Neurodegenerative disorder System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: PT Classification code 10012267 Term: Dementia System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: HLGT Classification code 10028037 Term: Movement disorders (incl parkinsonism) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: LLT Classification code 10048598 Term: Cognitive disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: LLT Classification code 10012285 Term: Dementia due to Pick's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: PT Classification code 10074616 Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-RO6958948 Pharmaceutical Form: Injection Trade Name: Vizamyl (flutemetamol(F-18)) Product Name: Vizamyl Pharmaceutical Form: Injection | Skåne University Hospital | Authorised | Female: yes Male: yes | Phase 2 | Sweden | ||||
| 17 | NCT02985879 | December 12, 2016 | 4 February 2019 | A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy (PSP) | Drug: placebo;Drug: ABBV-8E12 | AbbVie | Not recruiting | 40 Years | N/A | All | 378 | Phase 2 | United States;Australia;Canada;France;Germany;Italy;Japan;Spain | |
| 18 | NCT03058965 | November 29, 2016 | 1 April 2019 | Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers | Alzheimer Disease;Healthy Volunteers;Progressive Supranuclear Palsy | Drug: [18F]MNI-958;Drug: [18F]Florbetapir;Drug: DaTscan | Molecular NeuroImaging | Not recruiting | 50 Years | 90 Years | All | 12 | Early Phase 1 | United States | |
| 19 | NCT03080051 | August 2016 | 16 December 2017 | Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers | Progressive Supranuclear Palsy;Alzheimer Disease;Healthy Volunteers | Drug: [18F]MNI-952;Drug: [18F]Florbetapir | Molecular NeuroImaging | Not recruiting | 18 Years | 90 Years | All | 6 | Early Phase 1 | United States | |
| 20 | NCT02839642 | July 26, 2016 | 16 December 2017 | Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy | RIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical Trial | Progressive Supranuclear Palsy (PSP) | Drug: Rivastigmine;Drug: Placebo | Assistance Publique Hopitaux De Marseille | Recruiting | 41 Years | 80 Years | All | 106 | Phase 3 | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT02994719 | March 1, 2016 | 18 December 2018 | Gait Analysis in Neurological Disease | Gait Pattern Analysis in Neurological Disease | Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal | Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation | Beth Israel Deaconess Medical Center | Recruiting | 18 Years | 85 Years | All | 110 | N/A | United States | |
| 22 | NCT02658916 | February 22, 2016 | 18 March 2019 | Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 | A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003 | Supranuclear Palsy, Progressive | Drug: BIIB092 | Biogen | Not recruiting | 41 Years | 86 Years | All | 48 | Phase 1 | United States | |
| 23 | NCT02605785 | November 2015 | 1 April 2019 | A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy | A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: F-18 AV 1451 | Mayo Clinic | Recruiting | 40 Years | N/A | All | 134 | N/A | United States | |
| 24 | NCT02460094 | October 2, 2015 | 10 September 2018 | Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: BIIB092;Drug: Placebo | Biogen | Not recruiting | 41 Years | 86 Years | All | 48 | Phase 1 | United States | |
| 25 | NCT02494024 | July 2015 | 16 December 2017 | Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy | A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Single dose C2N-8E12;Drug: Single dose placebo | C2N Diagnostics | Not recruiting | 50 Years | 85 Years | All | 32 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT02460731 | May 2015 | 21 January 2019 | Young Plasma Transfusions for Progressive Supranuclear Palsy | A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Biological: Fresh Frozen Plasma | University of California, San Francisco | Not recruiting | 50 Years | 85 Years | All | 6 | Phase 1 | United States | |
| 27 | NCT02531360 | May 2015 | 9 January 2017 | Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies | Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies | Alzheimer's Disease (AD);Progressive Supranuclear Palsy (PSP);Cortical Basal Syndrome (CBS);Frontal Temporal Dementia (FTD) | Drug: [18F]MNI-815 (MNI-815) | Molecular NeuroImaging | Piramal Imaging SA | Not recruiting | 50 Years | 90 Years | Both | 7 | Phase 0 | United States |
| 28 | NCT02422485 | April 2015 | 11 June 2018 | A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy | A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Salsalate | Adam Boxer | Not recruiting | 50 Years | 85 Years | All | 10 | Phase 1 | United States | |
| 29 | EUCTR2013-003740-23-ES | 04/02/2015 | 21 May 2018 | Evaluation of masitinib in the treatment of Progressive Supranuclear Palsy | A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy MedDRA version: 14.1 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: masitinib 100mg Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: MASITINIB MESYLATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: masitinib 200mg Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: MASITINIB MESYLATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | AB Science | Not Recruiting | Female: yes Male: yes | 90 | Phase 3 | Spain | |||
| 30 | EUCTR2014-000422-38-SE | 19/09/2014 | 7 October 2014 | A study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of the protein tau | An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau | Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnostic conditions. MedDRA version: 17.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: PT Classification code 10053643 Term: Neurodegenerative disorder System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: LLT Classification code 10012285 Term: Dementia due to Pick's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: PT Classification code 10012267 Term: Dementia System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-AV-1451 Pharmaceutical Form: Injection | Skåne University Hospital, Region Skåne | Authorised | Female: yes Male: yes | Sweden | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT02167594 | July 2014 | 12 September 2016 | Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers | 18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers | Progressive Supranuclear Palsy;Corticobasal Degeneration | Drug: 18F-AV-1451;Drug: florbetapir F18 | Avid Radiopharmaceuticals | Not recruiting | 50 Years | 85 Years | Both | 29 | Phase 1 | United States | |
| 32 | NCT02133846 | May 2014 | 11 June 2018 | Safety Study of TPI-287 to Treat CBS and PSP | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy | Primary Four Repeat Tauopathies (4RT);Corticobasal Syndrome (CBS);Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD) | Drug: TPI 287 2 mg/m2;Drug: TPI-287 20 mg/m2;Drug: Placebo;Drug: TPI-287 6.3 mg/m2 | University of California, San Francisco | CBD Solutions;Tau Consortium | Not recruiting | 50 Years | 85 Years | All | 44 | Phase 1 | United States |
| 33 | EUCTR2012-005539-10-DE | 29/04/2014 | 2 October 2017 | Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions. | Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation | Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury. MedDRA version: 18.1 Level: PT Classification code 10039424 Term: Salivary hypersecretion System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xeomin Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: NT 101 CAS Number: 93384-43-1 Current Sponsor code: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intraglandular use Trade Name: Xeomin Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: NT 101 CAS Number: 93384-43-1 Current Sponsor code: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intraglandular use | Merz Pharmaceuticals GmbH | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | United States;Poland;Germany | |||
| 34 | NCT02103894 | February 2014 | 9 January 2017 | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects | Alzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;Tauopathies | Drug: [18F]T807 ([18F]MNI-777) | Molecular NeuroImaging | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | 85 Years | Both | 16 | Phase 1 | United States |
| 35 | NCT02214862 | March 2013 | 15 February 2016 | 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism | Pilot, Exploratory Study With [F18]-FDDNP-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism | Progressive Supranuclear Palsy;Multi-System Atrophy;Parkinsonism | Drug: [F18]-FDDNP | Fundacion Clinic per a la Recerca Biomédica | Not recruiting | 40 Years | N/A | Both | 40 | Phase 0 | Spain | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT01824121 | December 2012 | 19 February 2015 | Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism | Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial | Progressive Supranuclear Palsy | Biological: stem cell therapy | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Recruiting | 40 Years | N/A | Both | 25 | Phase 1/Phase 2 | Italy | |
| 37 | JPRN-UMIN000008959 | 2012/11/01 | 2 April 2019 | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy | Multiple system atrophy(MSA) Progressive supranuclear palsy (PSP) | hydrogen water pseudo-water (nitrogen filling water) | Juntendo University School of Medicine, Department of Neurology | Not Recruiting | 20years-old | 80years-old | Male and Female | 40 | Phase 1 | Japan | ||
| 38 | EUCTR2010-019159-23-GB | 22/12/2010 | 19 March 2012 | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy MedDRA version: 14.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Davunetide Product Code: AL-108 Pharmaceutical Form: Nasal spray INN or Proposed INN: Davunetide CAS Number: 211439-12-2 Current Sponsor code: AL-108 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Nasal spray Route of administration of the placebo: Intranasal use (Noncurrent) | Allon Therapeutics Inc | Authorised | Female: yes Male: yes | 300 | Phase 2/3 | Germany;United Kingdom;Canada;France;United States;Australia | |||
| 39 | EUCTR2010-019159-23-DE | 08/11/2010 | 22 April 2013 | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy MedDRA version: 14.1 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Davunetide Product Code: AL-108 Pharmaceutical Form: Nasal spray INN or Proposed INN: Davunetide CAS Number: 211439-12-2 Current Sponsor code: AL-108 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Nasal spray Route of administration of the placebo: Intranasal use (Noncurrent) | Allon Therapeutics Inc | Not Recruiting | Female: yes Male: yes | 300 | Phase 2/3 | France;United States;Canada;Australia;Germany;United Kingdom | |||
| 40 | NCT01110720 | October 2010 | 19 February 2015 | Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Davunetide;Drug: Placebo | Allon Therapeutics | Not recruiting | 41 Years | 85 Years | Both | 313 | Phase 2/Phase 3 | United States;Australia;Canada;France;Germany;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT01537549 | September 14, 2010 | 16 December 2017 | Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy | An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers | Progressive Supranuclear Palsy | Drug: alpha-lipoic acid and L-acetyl carnitine | Weill Medical College of Cornell University | Not recruiting | 40 Years | 75 Years | All | 11 | Phase 1/Phase 2 | United States | |
| 42 | EUCTR2008-007520-26-DE | 24/06/2010 | 10 February 2014 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III) | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III) | Progressive Supranuclear Palsy MedDRA version: 12.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy | Trade Name: Azilect Pharmaceutical Form: Tablet INN or Proposed INN: Rasagilin CAS Number: 161735-79-1 Other descriptive name: RASAGILINE MESILATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1 mg- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Klinikum der Universität München | Not Recruiting | Female: yes Male: yes | Phase 3 | Germany | ||||
| 43 | NCT01056965 | January 2010 | 15 April 2019 | Davunetide (AL-108) in Predicted Tauopathies - Pilot Study | A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies | Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent Aphasia | Drug: davunetide (AL-108, NAP);Drug: Placebo nasal spray | University of California, San Francisco | Not recruiting | 40 Years | 85 Years | All | 12 | Phase 1 | United States | |
| 44 | NCT01049399 | December 2009 | 19 February 2015 | Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy | A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: tideglusib;Drug: placebo | Noscira SA | i3 Research | Not recruiting | 40 Years | 85 Years | Both | 146 | N/A | United States;Germany;Spain;United Kingdom |
| 45 | EUCTR2009-013097-40-GB | 30/10/2009 | 19 March 2012 | A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS | A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS | Mild to Moderate Progressive Supranuclear Palsy MedDRA version: 12.0 Level: LLT Classification code 10036813 Term: Progressive supranuclear palsy MedDRA version: 12.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Pharmaceutical Form: Powder for oral suspension CAS Number: 865854-05-3 Current Sponsor code: NP031112 Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 600- Pharmaceutical form of the placebo: Powder for oral suspension Route of administration of the placebo: Oral use Product Name: NP031112 Product Code: NP031112 800mg Pharmaceutical Form: Powder for oral suspension CAS Number: 865854-05-3 Current Sponsor code: NP031112 Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 800- Pharmaceutical form of the placebo: Powder for oral suspension Route of administration of the placebo: Oral use | Noscira S.A. | Authorised | Female: yes Male: yes | 140 | Germany;United Kingdom;Spain | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT00703677 | September 2008 | 19 October 2017 | A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration | A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration | Progressive Supranuclear Palsy;Corticobasal Degeneration | Drug: Lithium | Westat | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 40 Years | 80 Years | All | 17 | Phase 1/Phase 2 | United States;United Kingdom |
| 47 | EUCTR2006-006166-42-DE | 17/07/2007 | 29 May 2012 | Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese - offene, prospektive Phase II-Studie - | Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese - offene, prospektive Phase II-Studie - | Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and donepezil did not point out a definite benefit. In contrast, first clinical observations concerning an effect with rivastigmine in PSP with dementia were promising. This may be due to the fact, that rivastigmine excerts a double action inhibiting both the acetylcholin- and the buturylcholinesterase. | Trade Name: Exelon 1,5 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE CAS Number: 123441032 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1,5- Trade Name: Exelon 3,0 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE CAS Number: 123441032 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3,0- Trade Name: Exelon 6,0 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE CAS Number: 123441032 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6- | University of Tuebingen | Authorised | Female: yes Male: yes | Phase 2 | Germany | ||||
| 48 | NCT00385710 | November 2006 | 19 February 2015 | Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) | Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: valproic acid;Drug: Placebo | Nantes University Hospital | Not recruiting | 45 Years | 75 Years | Both | 28 | Phase 2 | France | |
| 49 | NCT00382824 | September 2006 | 17 August 2015 | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study | Progressive Supranuclear Palsy;Atypical Parkinsonism | Drug: CoenzymeQ10 | Lahey Clinic | Not recruiting | 30 Years | N/A | Both | 62 | Phase 2/Phase 3 | United States | |
| 50 | EUCTR2005-000574-40-DE | 24/04/2006 | 19 March 2012 | Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A | Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A | PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 100000 and an age-adjusted prevalence of 6.4 / 100000, PSP is as common as motor-neuron disease. The progression of PSP is rapid and the median survival after onset of symptoms is 5-10 years. Presently, there is no known effective symptomatic or neuroprotective therapy for PSP. | Product Name: Coenzym Q10 Nanodispersion Product Code: ASK Nr. 21972 Pharmaceutical Form: Oral drops* INN or Proposed INN: Ubidecarenon CAS Number: 303-98-0 Current Sponsor code: Sanomit Other descriptive name: Coenzym Q10, Ubiquinon, Ubichinon Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 47.5-52.5 Pharmaceutical form of the placebo: Oral drops* Route of administration of the placebo: Oral use | Kompetenznetz Parkinson e.V. | Not Recruiting | Female: yes Male: yes | 30 | Germany | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT00139373 | May 2005 | 19 February 2015 | Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy | Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy | Supranuclear Palsy, Progressive | Drug: donepezil | Groupe Hospitalier Pitie-Salpetriere | Institut National de la Santé Et de la Recherche Médicale, France | Recruiting | 30 Years | 80 Years | Both | 16 | Phase 2 | France |
| 52 | NCT00605930 | April 2004 | 16 December 2017 | A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. | Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy | Dietary Supplement: Pyruvate, creatine, niacinamide;Dietary Supplement: Placebo | University of Louisville | Not recruiting | N/A | N/A | All | 20 | N/A | United States | |
| 53 | NCT00532571 | January 2004 | 25 June 2018 | Effects of Coenzyme Q10 in PSP and CBD | Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study | Progressive Supranuclear Palsy;Neurological Disorders | Drug: CoQ10 | Lahey Clinic | Not recruiting | 40 Years | N/A | All | Phase 2/Phase 3 | United States | ||
| 54 | NCT00005903 | June 2000 | 19 February 2015 | Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy | Dose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSP | Progressive Supranuclear Palsy | Drug: GDNF & Synchro Med Infusion System | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 15 | Phase 2 | United States | |
| 55 | NCT00211224 | April 2000 | 19 February 2015 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes) | Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Riluzole | King's College London | Assistance Publique - Hôpitaux de Paris;University of Ulm;Aventis Pharmaceuticals | Not recruiting | 30 Years | 80 Years | Both | 800 | Phase 3 | United Kingdom |